1. Home
  2. MCI vs VNDA Comparison

MCI vs VNDA Comparison

Compare MCI & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Barings Corporate Investors

MCI

Barings Corporate Investors

HOLD

Current Price

$20.50

Market Cap

423.8M

Sector

Finance

ML Signal

HOLD

Logo Vanda Pharmaceuticals Inc.

VNDA

Vanda Pharmaceuticals Inc.

HOLD

Current Price

$7.58

Market Cap

474.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCI
VNDA
Founded
1971
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
423.8M
474.0M
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
MCI
VNDA
Price
$20.50
$7.58
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$13.63
AVG Volume (30 Days)
40.4K
932.1K
Earning Date
01-01-0001
02-11-2026
Dividend Yield
8.46%
N/A
EPS Growth
N/A
N/A
EPS
1.82
N/A
Revenue
N/A
$212,074,000.00
Revenue This Year
N/A
$12.01
Revenue Next Year
N/A
$24.28
P/E Ratio
$9.88
N/A
Revenue Growth
N/A
11.12
52 Week Low
$12.96
$3.81
52 Week High
$19.24
$9.60

Technical Indicators

Market Signals
Indicator
MCI
VNDA
Relative Strength Index (RSI) 52.04 50.35
Support Level $20.19 $7.22
Resistance Level $21.05 $8.30
Average True Range (ATR) 0.52 0.42
MACD -0.01 -0.10
Stochastic Oscillator 50.15 33.51

Price Performance

Historical Comparison
MCI
VNDA

About MCI Barings Corporate Investors

Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Share on Social Networks: